Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
María E. Figueroa(University of Miami), Ari Melnick(Cornell University), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Patrick S. Ward(University of Pennsylvania), Jonathan D. Licht(University of Florida Health), Jay Patel(University of Utah), Bob Löwenberg(Unknown), Sung Choe(Agios Pharmaceuticals (United States)), Craig B. Thompson(Memorial Sloan Kettering Cancer Center), Valeria R. Fantin(AVEO Oncology (United States)), Neha Bhagwat(Resolve Therapeutics (United States)), Ruud Delwel(Erasmus MC Cancer Institute), Lucy A. Godley(University of Chicago), Kristy Wolniak(Northwestern University), Alan H. Shih(Tisch Hospital), Peter J.M. Valk(Erasmus MC Cancer Institute), Elisabeth Paietta(Montefiore Medical Center), Chao Lü(Columbia University Irving Medical Center), Wei Liu(Shanghai University of Traditional Chinese Medicine), Yushan Li(Northwest University), Aparna Vasanthakumar(University of Chicago), Justine Peeters(Erasmus MC), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Zhuoxin Sun(Dana-Farber Cancer Institute), Hugo F. Fernández(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 2,734